Search

Displaying results 6651 - 6660 of 7067 in total
  1. Drug

    CYT-6091

    go.drugbank.com/drugs/DB05991
    Experimental

    CYT-6091 (Aurimune) is an investigational small molecule made up of recombinant human tumor necrosis factor alpha (rhTNF) and thiolyated polyethylene glycol bound to the surface of 27 nm colloidal gold particles. It was under investagtio...

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    PRX-07034

    go.drugbank.com/drugs/DB05993
    Experimental

  3. Drug

    T-5224

    go.drugbank.com/drugs/DB05998
    Experimental

    T-5224 is an investigational drug developed to treat Sepsis-induced Acute Kidney Injury. It's mechanism of action is to inhibit c-Fos/activator protein-1.

  4. Drug

    TG-C

    go.drugbank.com/drugs/DB06004
    Investigational

  5. Drug

    ATHX-105

    go.drugbank.com/drugs/DB06008
    Investigational

    ATHX-105 is an investigational selective 5HT2c receptor agonist developed by Athersys Inc. for the treatment of Obesity.

  6. Drug

    AV-412

    go.drugbank.com/drugs/DB06021
    Investigational

  7. Drug

    GlycoPEG-GCSF

    go.drugbank.com/drugs/DB06022
    Experimental

    GlycoPEG-GCSF is a long-acting GlycoPEGylated granulocyte colony stimulating factor for the treatment of chemotherapy-induced neutropenia.

  8. Drug

    NGD-4715

    go.drugbank.com/drugs/DB06027
    Experimental

    NGD-4715 functions as a melanin-concentrating hormone receptor 1 antagonist.

  9. Drug

    BF-1

    go.drugbank.com/drugs/DB06029
    Experimental

    BF-1 is an investigational 5-HT2B receptor antagonist developed for the prophylaxis of Migraines.

  10. Drug

    RTP-801i

    go.drugbank.com/drugs/DB06048
    Investigational

    RTP-801i is an siRNA drug candidate designed to inhibit the expression of the hypoxia-inducible gene RTP801. The proposed primary indication for RTP-801i is the treatment of patients with neovascular (wet) Age-related Macular Degeneratio...